Results | Latest & Breaking News on Results | Photos, Videos, Breaking Stories and Articles on Results

you are here: Home News

Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
Sun Pharma’s hair loss drug Leqselvi faces uncertain road to launch
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth
Sun Pharma Q1 Preview: Strong US, domestic sales to aid profit growth but high R&D to drag margins
Sun Pharma Q1 preview: Subdued growth on weak Taro numbers, muted US sales
Sun Pharma Q1 PAT seen up 8.6% YoY to Rs 2,238.8 cr: Nirmal Bang
Sun Pharma Q3 PAT may dip 4% YoY to Rs 19,767 cr: Nirmal Bang
Q2 Preview | Sun Pharma consolidated net may drop 4% on high R&D costs
Sun Pharma Q1 Results Preview | Profit may rise 16%; revenue likely to dip 13%
Sun Pharma Q1 PAT may dip 15.5% YoY to Rs 1,673.1 cr: ICICI Direct
Sun Pharmaceutical Industries Q1 PAT seen up 23.7% YoY to Rs 1,786.1 cr: Prabhudas Lilladher
Sun Pharma Q3 Preview: Consolidated PAT to gain 10% YoY while revenue to rise 11%
Sun Pharmaceutical Industries Q1 PAT seen up 17.5% YoY to Rs 1,346.7 cr: KRChoksey
un Pharma Q1 PAT seen up 23.7% YoY to Rs 1,417.3 cr: ICICI Direct
Sun Pharma to announce Q4 results today; here what brokerages expect
Sun Pharma Q4 PAT seen up 82.2% YoY to Rs. 1,462.7 cr: Sharekhan
Sun Pharma's profit, revenue to rise in Q3; EBITDA margin may remain stable
Sun Pharma Q3 PAT seen up 56.7% YoY to Rs. 1,431.5 cr: Yash Securities
Sun Pharma Q3 PAT seen up 44.4% YoY to Rs 1,319 cr: ICICI Direct
Sun Pharma Q2 preview: Taro may hit revenue growth, trends in specialty portfolio key to watch
Sun Pharma Q4 profit, revenue expected to report healthy growth on low base
Sun Pharma Q2 PAT seen up 12% YoY to Rs. 1,114.8 cr: Emkay
Sun Pharma Q1 PAT seen up 12.3% YoY to Rs. 762.6 cr: Prabhudas Lilladher
Global brokerages stay positive on Sun Pharma, see 14-31% upside after Q4
Sun Pharma Q4 PAT may dip 36.1% YoY to Rs. 837 cr: Prabhudas Lilladher

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities

Sun Pharma’s hair loss drug Leqselvi faces uncertain road to launch

Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth

Sun Pharma Q1 Preview: Strong US, domestic sales to aid profit growth but high R&D to drag margins

Sun Pharma Q1 preview: Subdued growth on weak Taro numbers, muted US sales

Sun Pharma Q1 PAT seen up 8.6% YoY to Rs 2,238.8 cr: Nirmal Bang

Sun Pharma Q3 PAT may dip 4% YoY to Rs 19,767 cr: Nirmal Bang

Q2 Preview | Sun Pharma consolidated net may drop 4% on high R&D costs

Sun Pharma Q1 Results Preview | Profit may rise 16%; revenue likely to dip 13%

Sun Pharma Q1 PAT may dip 15.5% YoY to Rs 1,673.1 cr: ICICI Direct

Sun Pharmaceutical Industries Q1 PAT seen up 23.7% YoY to Rs 1,786.1 cr: Prabhudas Lilladher

Sun Pharma Q3 Preview: Consolidated PAT to gain 10% YoY while revenue to rise 11%

Sun Pharmaceutical Industries Q1 PAT seen up 17.5% YoY to Rs 1,346.7 cr: KRChoksey

un Pharma Q1 PAT seen up 23.7% YoY to Rs 1,417.3 cr: ICICI Direct

Sun Pharma to announce Q4 results today; here what brokerages expect

Sun Pharma Q4 PAT seen up 82.2% YoY to Rs. 1,462.7 cr: Sharekhan

Sun Pharma's profit, revenue to rise in Q3; EBITDA margin may remain stable

Sun Pharma Q3 PAT seen up 56.7% YoY to Rs. 1,431.5 cr: Yash Securities

Sun Pharma Q3 PAT seen up 44.4% YoY to Rs 1,319 cr: ICICI Direct

Sun Pharma Q2 preview: Taro may hit revenue growth, trends in specialty portfolio key to watch

Sun Pharma Q4 profit, revenue expected to report healthy growth on low base

Sun Pharma Q2 PAT seen up 12% YoY to Rs. 1,114.8 cr: Emkay

Sun Pharma Q1 PAT seen up 12.3% YoY to Rs. 762.6 cr: Prabhudas Lilladher

Global brokerages stay positive on Sun Pharma, see 14-31% upside after Q4

Sun Pharma Q4 PAT may dip 36.1% YoY to Rs. 837 cr: Prabhudas Lilladher